Logo

CombiMatrix to Obtain $10.5M in Stock Placement

Sep 16, 2005

NEW YORK, Sept. 16 (GenomeWeb News) - CombiMatrix will receive $10.5 million from a registered direct stock offering by its parent company, Acacia Research, the company said today.

 

Under the terms of the offering, Acacia will sell approximately 6.4 million shares of CombiMatrix's stock at $1.65 per share to a "select group of accredited investors." These investors will also obtain five-year warrants for the purchase of a total of approximately 1.6 million shares of common stock at an exercise price of $2.40 per share. Piper Jaffray is the exclusive placement agent for the transaction.

Breaking News
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.